Építés alatt – nem éles oldal
Belépés
Leállítva1. fázis

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

A legfontosabb adatok

Ki végzi
University of Southern California
Hol
Los Angeles (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1. fázis
Résztvevők
1 fő vett részt
Kezdés
2024. ápr. 1.
Befejezés
2025. szept. 9.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Biospecimen Collection
  • Computed Tomography
  • Magnetic Resonance Imaging
  • PEOX-based Polymer Encapsulated Paclitaxel FID-007
  • Tumor Resection
A regiszteradat frissítve
2025. szeptember 16.
Miért állt le
Slow accrual

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients must have histopathologically / cytologically confirmed diagnosis of head and neck squamous cell carcinoma
  • Sites of primary tumor allowed include the oral cavity and oropharynx only. Patients with recurrent disease that is amenable to surgery are eligible
  • Patients may have any stage cancer amenable to surgical resection
  • Patients must be able to provide an archival tissue specimen. Excisional biopsy or core needle biopsy specimens are allowed. Fine needle aspiration samples are not acceptable
  • Patients with oropharynx cancer must have p16 negative disease
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Leukocytes ≥ 3,000/mcL
  • Absolute neutrophil count ≥ 1,500/mcL
  • Platelets ≥ 100,000/mcl
  • Hemoglobin ≥ 9 g/dl
  • Total bilirubin ≤ 1.5 X institutional upper limit of normal
  • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 X institutional upper limit of normal
  • Creatinine ≤ 1.5 X institutional upper limit of normal
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:; Has not undergone a hysterectomy or bilateral oophorectomy; or; Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
  • Ability to understand and the willingness to sign a written informed consent

Ki nem vehet részt

  • Patients that have been previously treated with taxane chemotherapies
  • Patients that have previously received radiation to the site of planned surgery
  • Any diagnosis of immunodeficiency or patients receiving immunosuppressive therapy within 14 days of enrollment. Prednisone dose of ≤ 10mg is allowed
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to FID-007 or other agents used in study
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with primary sites of the nasopharynx, salivary gland, or skin
  • Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants

Helyszínek itt: Egyesült Államok

  • Los Angeles General Medical CenterLos Angeles, Egyesült Államok
  • USC / Norris Comprehensive Cancer CenterLos Angeles, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This study is being done to help identify future treatment options and better understand how to improve outcomes of patients with head and neck cancers after surgery.

A vizsgálat csoportja

  • Treatment (FID-007)A vizsgált kezelés

    Patients receive FID-007 IV over 30 minutes once a week for 3 weeks on days 1, 8, and 15 of a single 28 day cycle in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Patients undergo CT or MRI during screening and blood sample collection throughout the study.

    Kezelés: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, PEOX-based Polymer Encapsulated Paclitaxel FID-007 és Tumor Resection

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Window of Opportunity Study of Taxanes in Head and Neck Cancer
A regiszteradat frissítve
2025. szeptember 16.